Immunology Program

The Michael Glickman Lab



Michael Glickman
Michael S. Glickman, MD


We are broadly interested in the biology of mycobacteria, which include the major human pathogen M. tuberculosis, the nonpathogenic model organism M. smegmatis, and the cancer biotherapeutic agent BCG.

View Lab Overview

Research Projects

Michael Glickman Lab


A multilayered repair system protects the mycobacterial chromosome from endogenous and antibiotic-induced oxidative damage. Dupuy P, Howlader M, Glickman MS. Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19517-19527. doi: 10.1073/pnas.2006792117. Epub 2020 Jul 29. PMID: 32727901

Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling. Antonelli AC, Binyamin A, Hohl TM, Glickman MS, Redelman-Sidi G. Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18627-18637. doi: 10.1073/pnas.2004421117. Epub 2020 Jul 17. PMID: 32680964

Mycobacterial Mutagenesis and Drug Resistance Are Controlled by Phosphorylation- and Cardiolipin-Mediated Inhibition of the RecA Coprotease. Wipperman MF, Heaton BE, Nautiyal A, Adefisayo O, Evans H, Gupta R, van Ditmarsch D, Soni R, Hendrickson R, Johnson J, Krogan N, Glickman MS. Mol Cell. 2018 Oct 4;72(1):152-161.e7. doi: 10.1016/j.molcel.2018.07.037. Epub 2018 Aug 30. PMID: 30174294

Two Accessory Proteins Govern MmpL3 Mycolic Acid Transport in Mycobacteria.Fay A, Czudnochowski N, Rock JM, Johnson JR, Krogan NJ, Rosenberg O, Glickman MS. mBio. 2019 Jun 25;10(3):e00850-19. doi: 10.1128/mBio.00850-19.

The Canonical Wnt Pathway Drives Macropinocytosis in Cancer. Redelman-Sidi G, Binyamin A, Gaeta I, Palm W, Thompson CB, Romesser PB, Lowe SW, Bagul M, Doench JG, Root DE, Glickman MS. Cancer Res. 2018 Aug 15;78(16):4658-4670. doi: 10.1158/0008-5472.CAN-17-3199. Epub 2018 Jun 5.

View All Publications


Michael Glickman

Michael S. Glickman, MD


  • Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including regulated intramembrane proteolysis (the Rip1 pathway); double-strand-break repair and associated DNA damage responses; and cell envelope biosynthesis.
  • MD, Columbia University College of Physicians and Surgeons
Email Address
Office Phone
View physician profile
Physician profile


Michael Glickman, MD
Michael Glickman


John Buglino, PhD
John Buglino

Senior Research Scientist

Allison Fay, PhD
Allison Fay

Senior Research Scientist

Gil Redelman-Sidi, MD
Gil Redelman-Sidi

Assistant Attending Physician

Oyindamola  Adefisayo, BA
Oyindamola Adefisayo

Graduate Student

Anthony Antonelli
Anthony Antonelli

Graduate Student

Jamie Bean
Jamie Bean

TBRU Data Coordinator

Anna Binyamin

Lab Manager

Pierre Dupuy
Pierre Dupuy

Research Fellow

Adam Krebs
Adam Krebs

Graduate Student

Gaurav Sankhe
Gaurav Sankhe

Research Scholar

Miroslav Skular
Miroslav Skular

Research Technician

Charles  Vorkas, MD
Charles Vorkas

ID fellow

Lab Alumni
Lab Affiliations

Get in Touch


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michael S. Glickman discloses the following relationships and financial interests:

  • Takeda Millennium
    Provision of Services
  • Vedanta
    Ownership / Equity Interests; Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at

View all disclosures